Heparins are commonly used to prevent venous thromboembolism. Although they are effective anticoagulants, heparins have a high risk of adverse effects if used inappropriately. Safer heparin prescribing is achieved through careful patient selection by assessing the risk of venous thromboembolism. Consider the drugs' contraindications and precautions including renal function, concomitant medication use and spinal needle insertion. Comparative drug information needs to be considered when choosing the optimal heparin for an individual patient. The timing of perioperative heparin administration depends on the choice of heparin, type of surgery and type of anaesthesia. Patients should be carefully monitored during prophylaxis.
Introduction
Heparins are effective anticoagulants and can be used to prevent venous thromboembolism in hospitalised medical and surgical patients. In Australia it has been estimated that the overall prevalence of venous thromboembolism in all hospitalised patients is 2-3 per 1000 admissions. 1 There is therefore growing Australian and international encouragement for prophylaxis, so increased numbers of inpatients will be prescribed a heparin.
'Heparin' or 'heparins' refers to the following medications available in Australia:
n unfractionated heparin n low molecular weight heparins -dalteparin, enoxaparin n synthetic selective inhibitor of activated factor X -fondaparinux n heparinoid -danaparoid.
Although the benefits of using heparin in venous thromboembolism prophylaxis generally outweigh the risks, harm from low-dose heparin can be severe and the risks should not be ignored. While adverse effects are less common with low-dose heparin than with therapeutic doses of heparin, bleeding can still occur if other risk factors for bleeding are present, such as renal impairment or interaction with other drugs. Also, bleeding events can be expected to increase in frequency as the number of patients prescribed heparin for venous thromboembolism prophylaxis continues to increase. For example, a program of mandatory venous thromboembolism prophylaxis with low molecular weight heparin alone or in combination with warfarin has resulted in increased bleeding rates after hip and knee arthroplasty. 2 Incidents with anticoagulants including heparins (at all doses) continue to be commonly reported to incident reporting systems in Australia and the USA. 3, 4 Clinicians must consider the patient's safety when prescribing heparin as part of a strategy for venous thromboembolism prophylaxis as discussed in publications such as 'Safe prescribing of heparins for venous thromboembolism prophylaxis: a position statement of the NSW Therapeutic Advisory Group'. 5
Patients requiring venous thromboembolism prophylaxis
The risk of venous thromboembolism should be assessed in all adult patients before or on admission to hospital. Currently available guidelines differ regarding which patients require venous thromboembolism prophylaxis. [6] [7] [8] [9] [10] [11] [12] An Australian guideline for venous thromboembolism prophylaxis is currently under development. 13 Table 1 shows the current recommendations in the USA. 11
Contraindications and precautions
All patients should be assessed for contraindications and the precautions needed before starting prophylaxis. Absolute contraindications to heparin include known hypersensitivity, past or present heparin-induced thrombocytopenia and active bleeding.
Caution is required when prescribing heparin to patients with conditions that may increase the risk of bleeding (see box).
In these patients, the decision to prescribe heparin should be made on an individual basis balancing the relative benefit and harm. Tests for coagulation, such as prothrombin time, are not routinely required. 5 
Renal function
Patients with moderate to severe renal dysfunction have a higher risk of bleeding with some heparins. Assessment of renal function using creatinine clearance is important before Table 2 ). When choosing a heparin consider the clinical indication, patient factors (for example renal impairment), type of surgery and anaesthesia, dosing schedule, risk of heparin-induced thrombocytopenia, reversibility and cost. 5 Unfractionated heparin is not recommended for prophylaxis in hip or knee arthroplasty or trauma patients. 11
Timing and duration of heparin administration
Care should be taken to determine the optimal time for giving perioperative heparin. 5 
Patient monitoring
While routine clotting studies are not required during prophylaxis, patients need to be assessed for bleeding. Unless they are taking danaparoid, patients will need platelet counts every few days.
Bleeding
Easy bruising and petechial haemorrhages may precede frank bleeding. Nose bleeds, haematuria or melaena may be the first sign of bleeding, so check for these signs. 5 Bleeding can often be controlled by stopping the heparin. In some patients protamine sulfate may be considered for heparin reversal, however it does not reverse the effects of danaparoid and fondaparinux (Table 2 ). Patients with bleeding should undergo fluid management and resuscitation as required.
Thrombocytopenia
Unfractionated heparin, and to a lesser extent low molecular weight heparins, may cause heparin-induced thrombocytopenia.
A diagnosis of heparin-induced thrombocytopenia requires the presence of antibodies (heparin-dependent platelet antibodies) and one of the following events: 17 n unexplained platelet count fall of 30-50% from baseline n venous or arterial thrombosis n skin lesions at heparin injection sites n systemic anaphylactoid reactions.
Heparin-induced thrombocytopenia usually occurs 4-10 days (sometimes weeks) after starting heparin (earlier in patients exposed to heparin in the previous three months). Management requires cessation of heparin and alternative anticoagulation (danaparoid or lepirudin). Low molecular weight heparins should not be used in patients who have a history of heparininduced thrombocytopenia with unfractionated heparin.
A milder, reversible thrombocytopenia may also develop. In these cases antibodies are not present. If the platelet count remains greater than 100 x 10 9 /L, heparin may be continued. 17 Platelet counts should be measured intermittently in patients prescribed unfractionated heparin or low molecular weight heparins, and at baseline in patients prescribed fondaparinux, but are not required in patients prescribed danaparoid. 17 Recommendations for platelet count monitoring vary depending on the type of patient and the choice of heparin (Table 2) . 16, 17 
Future directions
The forthcoming Australian guidelines will clarify the indications for thromboembolism prophylaxis 13 , however practice may soon have to change. Dabigatran and rivaroxaban have recently been approved for use in Australia. As these anticoagulants can be given orally, they may supersede heparins in some indications.
Conclusion
Heparin is an effective but high-risk drug that can cause bleeding 
New drugs
Some of the views expressed in the following notes on newly approved products should be regarded as tentative, as there may be limited published data and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. As a result of fuller experience, initial comments may need to be modified. The Committee is prepared to do this. Before new drugs are prescribed, the Committee believes it is important that full information is obtained either from the manufacturer's approved product information, a drug information centre or some other appropriate source.
Dutasteride
Avodart ( Serum testosterone may increase, but prostate specific antigen concentrations will be reduced by dutasteride.
As dutasteride may affect the development of a male fetus the capsules should not be handled by pregnant women.
Like finasteride (see 'The price of urine', Aust Prescr 1995;18:26-7), the effect of dutasteride is modest. A placebo can improve a patient's symptom score by 2.3 points and the statistically significant change in urinary flow rate is only 1.3 mL/second greater than placebo. 1 Drug treatment should therefore only be used if self-management strategies do not work.
manufacturer provided only the product information
